US 12,325,759 B2
Anti-VEGF-anti-PD-L1 bispecific antibody, pharmaceutical composition of same, and uses thereof
Xiaoniu Miao, Guangdong (CN); Cheng Chen, Guangdong (CN); Zhijun Yuan, Guangdong (CN); Weifeng Huang, Guangdong (CN); Andy Tsun, Guangdong (CN); and Joanne Tsoyue Sun, Guangdong (CN)
Assigned to BIOTHEUS INC., Guangdong (CN)
Appl. No. 18/023,701
Filed by BIOTHEUS INC., Guangdong (CN)
PCT Filed Aug. 30, 2021, PCT No. PCT/CN2021/115308
§ 371(c)(1), (2) Date Feb. 27, 2023,
PCT Pub. No. WO2022/042719, PCT Pub. Date Mar. 3, 2022.
Claims priority of application No. 202010897917.1 (CN), filed on Aug. 31, 2020.
Prior Publication US 2023/0340158 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/468 (2013.01) [A61P 35/00 (2018.01); C07K 2317/565 (2013.01)] 34 Claims
 
1. A bispecific antibody comprising:
a first protein functional region targeting VEGF, and
a second protein functional region targeting PD-L1;
wherein the first protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof,
wherein the anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising:
HCDR1 with an amino acid sequence as set forth in SEQ ID NO: 21, HCDR2 with an amino acid sequence as set forth in SEQ ID NO: 22, and HCDR3 with an amino acid sequence as set forth in SEQ ID NO: 23; or
HCDR1 with an amino acid sequence as set forth in SEQ ID NO: 27, HCDR2 with an amino acid sequence as set forth in SEQ ID NO: 22, and HCDR3 with an amino acid sequence as set forth in SEQ ID NO: 28; and
wherein the anti-VEGF antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) comprising:
LCDR1 with an amino acid sequence as set forth in SEQ ID NO: 24, LCDR2 with an amino acid sequence as set forth in SEQ ID NO: 25, and LCDR3 with an amino acid sequence as set forth in SEQ ID NO: 26;
wherein the second protein functional region is an anti-PD-L1 single-domain antibody,
wherein the anti-PD-L1 single-domain antibody comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1 with an amino acid sequence as set forth in SEQ ID NO: 29, HCDR2 with an amino acid sequence as set forth in SEQ ID NO: 30, and HCDR3 with an amino acid sequence as set forth in SEQ ID NO: 31.